Spanish Lung Adenocarcinoma Trial (SLAT) of customized treatment based on EGFR mutations (mut) and BRCA1 mRNA expression: Ancillary analyses of Abraxas and RAP80 expression

8037 Background: We carried out a study in metastatic NSCLC where treatment was customized according to EGFR mut status and BRCA1 mRNA levels. Loss of BRCA1 function increases sensitivity to cisplatin and resistance to antimicrotubule drugs (Quinn et al. Cancer Res 2003). The Abraxas-RAP80 complex can modulate BRCA1 function (Wang et al. Science 2007). A gene signature including BRCA1 predicts poor survival (Deeb et al. Cancer Res 2007). Methods: 93 patients (p) with lung adenocarcinoma or large-cell carcinoma were screened for EGFR Δ746–750 deletion and L858R mut and BRCA1 mRNA expression. 15 p with EGFR mut received erlotinib; 78 p without mut received chemotherapy according to BRCA1 levels (low: gemcitabine/cisplatin; intermediate: docetaxel/cisplatin; high: docetaxel alone). In addition, Abraxas and RAP80 mRNA expression were examined in 60/78 p without mut. Results: With a median follow-up of 10 months (m) for all 92 p, median survival (MS) has not been reached in 15 p with EGFR mut. MS has not been ...